Guardant Health Surges After FDA Approval

Shares of Guardant Health surged after the FDA approved its liquid biopsy-based cancer screening technology, which analyzes blood samples to detect early signs of cancer. The approval expands the company's ability to reach the mass market for early cancer detection, considered one of the most promising areas in biotech. Investors viewed the news as confirmation of Guardant Health's competitive edge over other players in the liquid biopsy space. The technology allows cancer indicators to be detected through a simple blood draw without invasive procedures, simplifying population-wide screening. Analysts say the FDA approval could serve as a catalyst for revenue growth in coming quarters and strengthen the company's position against other diagnostic startups.